| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 28, 2009
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody...
-
Sep 24, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in...
-
Sep 23, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases...
-
Jul 15, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology...
-
Jul 8, 2009
Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an...
